ChromoCure, Inc. Announces Co-Development Agreement for New CS300 Scanner Series in Preparation for Nationwide Distribution

RENO, NV--(Marketwire - September 04, 2009) -

Highlighted Links

MacReport Media Publishing

ChromoCure, Inc. (PINKSHEETS: KKUR) announced today it executed a Technology Co-Development Agreement with its primary cell preparation and application technology supplier. The co-development agreement calls for the joint-development of a fully integrated chromosomal scanner system for nation-wide distribution to pathology and related cancer detection labs.

The agreement calls for the technical collaboration and partnership between the companies and joint technical research and development efforts to complete a fully automated hybridization system allowing for a complete 'end-to-end' chromosomal scanning solution. The company has named the system "CS300" and represents a significant advancement in automating every aspect of the preparation and scanning cycles of the CS200's current automation capabilities and design.

The feature set of the new system is anticipated to include:

--  Ability to perform a full 23-pair chromosomal cross-sectioning for
    every cell within a sample
--  Integration of solid tissue disaggregation inputs and automation
--  Integration for inputs derived from de-paraffinization protocols for
    histo-pathology research and patient tissue archive recovery and assay
--  Parallel DNA-probe insertions across hybridizing channels for rapid
    scans across multiple chromosomes
--  Ability to integrate solid tumor incubation equipment for therapeutic
    and cancer cure protocols testing.
    

The remainder of the Company's plan of operations for 2009 will continue to be executed and investors updated accordingly.

Updates will be timely published on the following:

--  Initial scanner installations with diagnostic labs
--  Elimination of significant long-term liabilities and removal from the
    Balance Sheet
--  Additional appointments to the Company's Advisory Boards
--  Acquisition of profitable labs to expand the company's operations
--  Release of technology and industry White Papers.
    

About ChromoCure

ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company's systems measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology superior and will become the gold standard for cancer detection worldwide.

The Company's technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.

Safe-Harbor Statement

This release contains statements or projections regarding future performance that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.